U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06825091) titled 'Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)' on Jan. 26.
Brief Summary: The ASPIRE study is a Phase III randomized, single-center study designed to evaluate whether adaptive stereotactic body radiotherapy (SBRT) offers superior clinical benefits compared to standard image-guided SBRT for patients with localized prostate cancer. It aims to explore whether adaptive SBRT can improve urinary outcomes while maintaining effective cancer control.
This interventional study is randomized, single-institution, and includes 320 participants with localized prostate cancer. Patients will be stratified bas...